1100_Barrett.ppt

Approaching the In Silico Child

B_Bernhard_SV_28.02.06.pdf

Can Healthcare Systems Afford Targeted Medicines?

H._Fuder_IV_02.03.06.pdf

Gaps Between Biomarkers and Surrogate Endpoints: CNS

Krishna_SII_28.02.06.ppt

Approaches to First-In-Man and Beyond: Early Evidence of Target Engagement with Biomarkers and Innovative Clinical Trial Designs.

1500_Lesko.ppt

Tools to Reduce Phase III Trial Failures.

J._L_tz_SVII_06.03.06.pdf

Perspective of the German Medicines Agency (BfArM). BfArM after reorganisation of the structure.

B._Meibohm_SIII_28.02.06.pdf

Interplay between Drug Metabolizing Enzymes

J._Schentag_SIV_01.03.06.pdf

The Gap Between Biomarkers and Surrogate Endpoints in the Development of Anti-Infectives.

B._Schug_WS_C_09.03.06.pdf

Drug Interaction Studies

0830_St_rzebecher.ppt

The Feasibility of Personalized Medicine.

EU-IMPD.pdf

What is required for first into man? The EU IMPD.

Throm_SVII_01.03.06.pps

Innovation or Stagnation - Perspective of Pharmaceutical Industry.

1200_Wensing.pdf

From Preclinical Data to Proof of Concept – Strategies for First to Man Studies.

1630_Z_hlsdorf.ppt

The gap between biomarkers and surrogate endpoints Oncology